News
-
-
-
-
PRESS RELEASE
Tryp Therapeutics Provides Update on Plan of Arrangement With Exopharm Limited and Announces Voluntary Trading Halt
Tryp Therapeutics, Inc. announces shareholder approval and completion of plan of arrangement with Exopharm Limited. Anticipates trading on ASX as Tryptamine Therapeutics Limited (ticker symbol TYP) in May 2024 -
-
PRESS RELEASE
Tryp Therapeutics Announces 99.92% Votes Cast by Shareholders in Favor of Arrangement Agreement at Annual General and Special Meeting of Securityholders, and Receipt of Final Order
Tryp Therapeutics announces securityholders' approval of Arrangement with Exopharm Limited CAN 163 765 991 at annual meeting. Closing expected in late March 2024 -
PRESS RELEASE
Tryp Therapeutics Obtains Interim Order for Plan of Arrangement and Provides Details of Shareholder Meeting
Tryp Therapeutics, Inc. obtains interim court order for proposed arrangement with Exopharm Limited ACN 163 765 991. Meeting scheduled for March 8, 2024, in Toronto, Ontario, to vote on the arrangement resolution -
-
PRESS RELEASE
Tryp Therapeutics Announces Significant Milestone in Its Clinical Trial Program for Trp-8803 (IV-infused Psilocin)
Tryp Therapeutics, Inc. announces approval from the Human Research Ethics Committee (HREC) in Australia to start a groundbreaking Phase 1 clinical trial of TRP-8803, an IV-infused psilocin, in healthy human volunteers. The trial aims to optimize doses and infusion rates of IV-administered psilocin to achieve targeted blood levels and will also collect real-time EEG data to monitor changes in EEG patterns associated with the psychedelic state. This milestone is a significant advancement in psychedelic medicine and is expected to provide crucial data for future Phase 2 studies. TRP-8803, a proprietary formulation of psilocin, is anticipated to have faster onset and shorter treatment duration, aiming to treat certain neuropsychiatric disorders with more commercial feasibility. Tryp Therapeutics is also making progress with its TRP-8802 oral psilocybin clinical trial for irritable bowel syndrome patients, with patient dosing expected in the first half of 2024. -
PRESS RELEASE
Tryp Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial for the Treatment of Fibromyalgia at The University of Michigan
Tryp Therapeutics Inc. is pleased to announce the dosing of the first patient in a Phase 2a clinical trial for fibromyalgia using their proprietary IV-infused psilocin, TRP-8802. With positive results, the company aims to further develop TRP-8803 to provide relief to millions of patients suffering from chronic pain. Learn more about Tryp's innovative therapies at www.tryptherapeutics.com.
![Accesswire](/assets/images/accesswire-inline.png)
-
Eagle Plains Announces Conditional Approval of Warrant Expiry Extension
-
Goldflare Announces Changes in Leadership
-
Gina Corena & Associates Participates in 2024 Nevada Justice Association Annual Summer Gala This Weekend
-
Canada Jetlines Announces Loan
-
Pixalate Introduces EMEA Connected TV (CTV) Supply-Side Platform (SSP) Market Share Rankings: Magnite No. 1 With 43% Market Share in Q1 2024
![EQS Group](/assets/images/eqs-group.png)
-
EQS-Adhoc: VOLKSWAGEN AKTIENGESELLSCHAFT: Volkswagen AG resolves on investment by Volkswagen of initially 1 billion USD in Rivian Automotive, Inc., and intends to establish a joint venture
-
CompuGroup Medical strengthens market position in Northern Europe with the acquisition of Norwegian Pridok
-
EQS-Adhoc: CompuGroup Medical SE & Co. KGaA: CompuGroup Medical acquires Pridok AS
-
Molten Ventures Plc: HOL-Holding(s) in Company
-
Annual General Meeting 2024 of Meyer Burger approves all motions
![Les Echos](/assets/images/les-echos.png)
-
RESULTS OF THE COMBINED GENERAL MEETING ON JUNE 24, 2024
-
Schneider Electric announces the reference share price and the initial conversion/exchange ratio of its new bonds convertible into new shares and/or exchangeable for existing shares (OCEANEs) due 2031 and the results of the repurchase of the OCEANEs
-
FREY signs new financing for €400m
-
Schneider Electric announces the success of its offering of bonds convertible into new shares and/or exchangeable for existing shares (OCEANEs) due 2031 for a nominal amount of €750 million
-
Cie du Bois Sauvage: Buy back of own shares – week from 17/06/2024 to 21/06/2024